BDNF and myeloid sarcoma: In this context, we have reviewed preclinical studies on MS animal models, including attenuating the reactivity of pro-inflammatory/neurodegenerative microglia, stabilizing the blood–brain barrier (BBB), and enhancing neurotrophin expression (Figure 1).